ebomi
Colour theme
Sign in
Insider · CIK 0001250195

Elms Steve

CIK 0001250195 Name as filed on the most recent filing

Filed as Elms Steve (35)

45 transaction lines · from 35 filings · filed 2010-03-12 to 2026-03-09 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

15 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.

Transactions filed by this insider
Direction Date Issuer Code Shares Price Value USD Filing
2026-03-06 Adma Biologics, Inc.
ADMA 		P, Open-market purchase 7,000 acquired 15.39 107,730.00 Form 4, filing 0001140361-26-008363
2026-03-05 Adma Biologics, Inc.
ADMA 		P, Open-market purchase 7,000 acquired 15.67 109,690.00 Form 4, filing 0001140361-26-008363
2025-06-16 Adma Biologics, Inc.
ADMA 		S, Open-market sale 194,749 disposed 20.24 3,941,719.76 Form 4, filing 0001140361-25-022713
2025-06-13 Adma Biologics, Inc.
ADMA 		S, Open-market sale 137,931 disposed 20.82 2,871,723.42 Form 4, filing 0001140361-25-022713
2025-06-12 Adma Biologics, Inc.
ADMA 		S, Open-market sale 92,941 disposed 21.69 2,015,890.29 Form 4, filing 0001140361-25-022713
2024-12-23 Marker Therapeutics, Inc.
MRKR 		P, Open-market purchase 11,085 acquired 3.20 35,472.00 Form 4, filing 0001104659-24-131704
2024-03-19 Adma Biologics, Inc.
ADMA 		S, Open-market sale 411,829 disposed 6.08 2,503,920.32 Form 4, filing 0001140361-24-014226
2024-03-18 Adma Biologics, Inc.
ADMA 		S, Open-market sale 49,887 disposed 6.01 299,820.87 Form 4, filing 0001140361-24-014226
2024-03-15 Adma Biologics, Inc.
ADMA 		S, Open-market sale 183,008 disposed 6.01 1,099,878.08 Form 4, filing 0001140361-24-013634
2024-03-14 Adma Biologics, Inc.
ADMA 		S, Open-market sale 448,276 disposed 6.05 2,712,069.80 Form 4, filing 0001140361-24-013634
2024-03-13 Adma Biologics, Inc.
ADMA 		S, Open-market sale 407,000 disposed 6.21 2,527,470.00 Form 4, filing 0001140361-24-013634
2021-06-29 Elevation Oncology, Inc.
ELEV 		P, Open-market purchase 187,500 acquired 16.00 3,000,000.00 Form 4, filing 0001209191-21-044561
2021-03-16 Marker Therapeutics, Inc.
MRKR 		P, Open-market purchase 1,142,857 acquired 1.75 1,999,999.75 Form 4, filing 0001209191-21-021769
2019-07-15 Sunesis Pharmaceuticals Inc
SNSS 		P, Open-market purchase 2,500,000 acquired 0.60 1,500,000.00 Form 4, filing 0000899243-19-019602
2018-07-10 Loxo Oncology, Inc.
LOXO 		S, Open-market sale 1,400,000 disposed 179.43 251,202,000.00 Form 4, filing 0000899243-18-019810
2017-12-19 Loxo Oncology, Inc.
LOXO 		S, Open-market sale 250,000 disposed 80.50 20,125,000.00 Form 4, filing 0000950142-17-002235
2017-11-22 Loxo Oncology, Inc.
LOXO 		S, Open-market sale 500,000 disposed 75.00 37,500,000.00 Form 4, filing 0000950142-17-002107
2017-01-10 Loxo Oncology, Inc.
LOXO 		P, Open-market purchase 160,000 acquired 31.00 4,960,000.00 Form 4, filing 0000950142-17-000108
2016-07-06 Syros Pharmaceuticals, Inc.
SYRS 		P, Open-market purchase 400,000 acquired 12.50 5,000,000.00 Form 4, filing 0000950142-16-004060
2016-05-17 Loxo Oncology, Inc.
LOXO 		P, Open-market purchase 232,558 acquired 21.50 4,999,997.00 Form 4, filing 0000950142-16-003763
2015-12-11 Loxo Oncology, Inc.
LOXO 		P, Open-market purchase 200 acquired 27.50 5,500.00 Form 4, filing 0000950142-15-002621
2015-12-09 T2 Biosystems, Inc.
TTOO 		P, Open-market purchase 307,692 acquired 9.75 2,999,997.00 Form 4, filing 0000950142-15-002576
2015-11-17 Loxo Oncology, Inc.
LOXO 		P, Open-market purchase 265,000 acquired 26.50 7,022,500.00 Form 4, filing 0000950142-15-002461
2015-11-13 Loxo Oncology, Inc.
LOXO 		P, Open-market purchase 1,955 acquired 27.47 53,704.24 Form 4, filing 0000950142-15-002434
2015-11-12 Loxo Oncology, Inc.
LOXO 		P, Open-market purchase 76,714 acquired 27.65 2,121,318.54 Form 4, filing 0000950142-15-002434
2015-04-24 Esperion Therapeutics, Inc.
ESPR 		S, Open-market sale 61,726 disposed 106.10 6,549,128.60 Form 4, filing 0000950142-15-000894
2015-04-24 Esperion Therapeutics, Inc.
ESPR 		S, Open-market sale 5,743 disposed 108.00 620,244.00 Form 4, filing 0000950142-15-000894
2015-04-23 Esperion Therapeutics, Inc.
ESPR 		S, Open-market sale 150,000 disposed 109.10 16,365,000.00 Form 4, filing 0000950142-15-000894
2015-01-27 Versartis, Inc.
VSAR 		P, Open-market purchase 145,000 acquired 17.25 2,501,250.00 Form 4, filing 0000950142-15-000194
2015-01-23 Agile Therapeutics Inc
AGRX 		P, Open-market purchase 811,966 acquired 5.85 4,750,001.10 Form 4, filing 0000950142-15-000157
2014-08-12 T2 Biosystems, Inc.
TTOO 		P, Open-market purchase 454,545 acquired 11.00 4,999,995.00 Form 4, filing 0001104659-14-061090
2014-08-06 Loxo Oncology, Inc.
LOXO 		P, Open-market purchase 413,077 acquired 13.00 5,370,001.00 Form 4, filing 0001140361-14-031042
2014-08-06 Loxo Oncology, Inc.
LOXO 		P, Open-market purchase 413,077 acquired 13.00 5,370,001.00 Form 4, filing 0001140361-14-031039
2014-04-21 Transenterix Inc.
TRXC 		P, Open-market purchase 1,037,767 acquired 4.00 4,151,068.00 Form 4, filing 0000950142-14-000941
2014-03-26 Versartis, Inc.
VSAR 		P, Open-market purchase 60,000 acquired 21.00 1,260,000.00 Form 4, filing 0001209191-14-023549
2014-03-21 Durata Therapeutics, Inc.
DRTX 		S, Open-market sale 2,649 disposed 15.57 41,255.00 Form 4, filing 0000950142-14-000705
2014-03-20 Durata Therapeutics, Inc.
DRTX 		S, Open-market sale 98,000 disposed 15.74 1,542,588.60 Form 4, filing 0000950142-14-000705
2013-11-14 Zeltiq Aesthetics Inc
ZLTQ 		S, Open-market sale 575,000 disposed 12.22 7,026,500.00 Form 4, filing 0000950142-13-002267
2013-10-22 Adma Biologics, Inc.
ADMA 		P, Open-market purchase 411,765 acquired 8.50 3,500,002.50 Form 4, filing 0000950142-13-002123
2013-07-01 Esperion Therapeutics, Inc.
ESPR 		P, Open-market purchase 238,119 acquired 14.00 3,333,666.00 Form 4, filing 0001179110-13-011142
2013-05-21 Ambit Biosciences Corp
AMBI 		P, Open-market purchase 423,635 acquired 8.00 3,389,080.00 Form 4, filing 0001181431-13-029562
2012-07-24 Durata Therapeutics, Inc.
DRTX 		P, Open-market purchase 1,111,111 acquired 9.00 9,999,999.00 Form 4, filing 0000950142-12-001608
2012-02-07 Cempra, Inc.
CEMP 		P, Open-market purchase 1,213,663 acquired 6.00 7,281,978.00 Form 4, filing 0000950142-12-000248
2011-10-24 Zeltiq Aesthetics Inc
ZLTQ 		P, Open-market purchase 769,231 acquired 13.00 10,000,003.00 Form 4, filing 0001181431-11-053467
2010-03-10 MAP Pharmaceuticals, Inc.
MAPP 		S, Open-market sale 2,090 disposed 16.15 33,753.50 Form 4, filing 0000950142-10-000415

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 6
  • Open-market sale 9
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. ELMS STEVE, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001250195

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.